Full Press Release Details
Sinovac Files 2014 Annual Report on Form
BEIJING, April 29, 2015 -- Sinovac Biotech Ltd. (Nasdaq:
SVA), a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization
of vaccines, announced today that it has filed its 2014 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
for the year ended December 31, 2014 on April 29, 2015. The Annual Report on Form 20-F is now available on the Company's website
under SEC Filing in the Investor Relations section.
The Company will provide a hard copy of its complete audited
financial statements to its shareholders upon request, free of charge. Requests for a hard copy of the 2014 Annual Report
can be made through the Contact IR page in the Investor Relations section of the Company's website by submitting complete mailing
details on the request form.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company
that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious
diseases. Sinovac's product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza
(avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009, Sinovac was the first company worldwide to receive approval
for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program.
The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. Sinovac has
filed a new drug application with the China Food & Drug Administration for its proprietary enterovirus 71 vaccine, having been
proven effective in preventing hand, foot and mouth disease in infants and children during its Phase III clinical trial. The Company
is currently developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides
vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring
growth opportunities in international markets. The Company has exported select vaccines to Mexico, Mongolia, Nepal, and the Philippines,
and was recently granted a license to commercialize its hepatitis A vaccine in Chile. For more information, please visit the Company's
website at www.sinovac.com .
Sinovac Biotech Ltd.
Helen Yang / Chris Lee
Tel: +86-10-8279-9659 / 9696
Fax: +86-10-6296-6910
Email: ir@sinovac.com
Email: william.zima@icrinc.com